ArticleHuman vaccines & immunotherapeutics2025
Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lactate metabolism-driven lactylation: paradoxical modulation of intestinal inflammation and malignancy.Journal of translational medicine · 2026Review
- Advances in immunotherapy for thyroid malignancies: from molecular targets to clinical outcomes.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research aims to explore the historical evolution, key research areas, and new trends in PD-1/PD-L1 immunotherapy for hepatocellular carcinoma (HCC) over the last twenty years, focusing on structural and temporal dynamics. The Web of Science Core Collection (WoSCC) database was used to gather studies on PD-1/PD-L1 immunotherapy for HCC.CiteSpace and HistCite were utilized for a bibliometric analysis to investigate the historical progression, research evolution, and emerging trends in this area. In the last two decades, 2804 papers on PD-1/PD-L1 immunotherapy in HCC have been published, comprising 541 reviews and contributions from 13,796 authors across 2,659 institutions. Since 2014, the number of annual publications has significantly increased, with extensive international collaboration. Several active research topics have emerged, covering 72 disciplines, generating 561 keywords, and 1,199 articles that experienced citation bursts. Cluster analysis of keywords revealed five emerging subfields: lenvatinib, immune escape, immne checkpoint inhibitors, prognostic models, and tumor microenvironment. According to the "Timeline visualization of references," classic topics include CMTM6, regulatory T cells, liver transplantation, and bioinformatics analysis, while emerging topics include prognosis, lenvatinib, transarterial chemoembolization, hepatic arterial infusion chemotherapy, and single-cell RNA sequencing. This study sheds light on the current status and developing trends in PD-1/PD-L1 immunotherapy research for HCC, offering researchers valuable insights to identify crucial areas and explore new research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.